COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

"Palivizumab Therapy for RSV-bronchiolitis"

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02442427
Recruitment Status : Completed
First Posted : May 13, 2015
Last Update Posted : February 27, 2018
Information provided by (Responsible Party):
Hamad Medical Corporation

Brief Summary:

There is a growing body of literature suggesting that monoclonal antibody could be efficacious in infants with RSV-bronchiolitis, well tolerated with no or clinically insignificant adverse effects.

"The investigators hypothesize that a single dose of iv palivizumab 15 mg/kg in diagnosed infants <3 months old with RSV bronchiolitis will result in fewer infants with readmissions to infirmary/observation or hospital for relapse during 3 weeks of follow-up after discharge".

Condition or disease Intervention/treatment Phase
Respiratory Syncytial Virus-bronchiolitis Drug: Palivizumab Other: Placebo Phase 3

Detailed Description:


The study will be conducted between September 2014 and April 2018 in the short stay unit of the Pediatric Emergency Center (PEC) of Hamad General Hospital, the only pediatric emergency facility in the State of Qatar. The PEC serves an average of 280 000 patients annually and manages 42 beds in a short stay infirmary unit, to which patients are admitted if they are too ill to be sent home but do not need the intensive care unit. Patients admitted to the unit are assessed at least every 6 hours by a pediatrician to determine readiness for discharge. The length of stay in the unit for bronchiolitis ranges from 6 to 168 hours. In 2012, the investigators saw 8718 infants and young children in 10 666 visits for bronchiolitis. Infants aged ≤3 months presenting to the unit for treatment of viral bronchiolitis will be eligible for the study. Consecutive patients will be recruited except when a study nurse is unavailable or the unit is too busy to recruit.


Patients will be examined on presentation, and those needing additional treatment or observation will be admitted to the short stay infirmary unit. Consecutive patients with bronchiolitis will be assessed for study eligibility within 2 hours. Eligible patients will be enrolled after obtaining written consent. For those who consent, plain chest radiography, and nasopharyngeal swabs will be taken for RSV detection. If the patient has a positive RSV rapid antigen test, patients will be randomized to receive one of the study arms. Bronchiolitis severity score will be measured initially at the start of treatment and then at 12-hour, 24-hour, 36-hour and 48-hour thereafter. The medical team in addition to the parents and patients will be blinded to the medication delivered. Adverse effects in each group will be carefully monitored and documented. Patients will be sent home with salbutamol metered-dose inhalers with an appropriately sized Aerochamber with mask attachment. Daily follow-up by study nurse by telephone is mandatory for 1 week after discharge and then once a week for 2 weeks thereafter. The patient could return to the pediatric emergency center earlier if needed. At all revisits for the same illness, nasopharyngeal swabs will be taken for RSV rapid antigen test and the result recorded.

Study Intervention:

  • Active arm: A single dose of IV palivizumab 15 mg per kilogram body weight (maximum dose =100 mg).
  • Control arm: Placebo (an equivalent volume of 0.9% normal saline).

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 420 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Treatment of Respiratory Syncytial Virus Bronchiolitis in Young Infants With Humanized Monoclonal Antibody: A Randomized Clinical Trial (Palivizumab Study)
Study Start Date : September 2014
Actual Primary Completion Date : February 1, 2018
Actual Study Completion Date : February 1, 2018

Resource links provided by the National Library of Medicine

Drug Information available for: Palivizumab

Arm Intervention/treatment
Active Comparator: Palivizumab
A single dose of IV palivizumab
Drug: Palivizumab
A single dose of IV palivizumab 15 mg per kilogram body weight (maximum dose =100 mg). The study medication will be given by IV infusion over 30 minutes using a syringe infusion pump.
Other Name: Monoclonal antibody

Placebo Comparator: Placebo
An equivalent volume of 0.9% normal saline.
Other: Placebo
An equal volume of 0.9% normal saline
Other Name: 0.9% Normal saline

Primary Outcome Measures :
  1. Readmission to either infirmary/observation or hospital or PICU during 3 weeks of follow-up after discharge [ Time Frame: 3 weeks ]

Secondary Outcome Measures :
  1. Time to medical readiness for discharge [ Time Frame: 4 weeks ]
  2. Revisit to any medical facility for the same illness [ Time Frame: 4 weeks ]
  3. Admission to PICU during initial admission [ Time Frame: 4 weeks ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   up to 3 Months   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Infants ≤ 3 months-old, presenting to the main pediatric ER with acute bronchiolitis associated with positive RSV rapid antigen test.

Exclusion Criteria:

  • Patients will be excluded from the study if they had 1 or more of the following characteristics:

    • Received monoclonal antibody or IVIG within the last 3 months prior to randomization.
    • Receipt of steroids within 2 days before randomization.
    • Hypersensitivity to monoclonal antibodies or immunoglobulin products.
    • Immunodeficiency.
    • Suspected sepsis.
    • Seizure disorders.
    • Neuromuscular disorders.
    • Congenital heart disease.
    • Major congenital anomalies of respiratory tract.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02442427

Layout table for location information
Hamad Medical Corporation
Doha, Qatar, 3050
Sponsors and Collaborators
Hamad Medical Corporation
Layout table for investigator information
Principal Investigator: Dr. Khalid Alansari Hamad Medical Corporation, Doha, Qatar

Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Hamad Medical Corporation Identifier: NCT02442427    
Other Study ID Numbers: 14302/14
First Posted: May 13, 2015    Key Record Dates
Last Update Posted: February 27, 2018
Last Verified: January 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Keywords provided by Hamad Medical Corporation:
Respiratory syncytial virus
Additional relevant MeSH terms:
Layout table for MeSH terms
Bronchial Diseases
Respiratory Tract Diseases
Lung Diseases, Obstructive
Lung Diseases
Respiratory Tract Infections
Antibodies, Monoclonal
Immunologic Factors
Physiological Effects of Drugs
Antiviral Agents
Anti-Infective Agents